The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia? (Q44905973)

7 December 2017

The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia? (English)

1 reference

7 December 2017

1 reference

Grant S

1

1 reference

7 December 2017

1 December 2004

1 reference

7 December 2017

1 reference

7 December 2017

18

1 reference

7 December 2017

12

1 reference

7 December 2017

1931-1933

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.leu.2403522

7 December 2017

0 references

cites work

Histone deacetylase inhibitor NVP-LAQ824 has significant activity against myeloid leukemia cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

Histone deacetylases and cancer: causes and therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

Translating the Histone Code

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

Butyric acid, a potent inducer of erythroid differentiation in cultured erythroleukemic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

Second generation hybrid polar compounds are potent inducers of transformed cell differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

Induction of apoptosis in U937 human leukemia cells by suberoylanilide hydroxamic acid (SAHA) proceeds through pathways that are regulated by Bcl-2/Bcl-XL, c-Jun, and p21CIP1, but independent of p53

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

Cellular Events Involved in Butyric Acid-Induced T Cell Apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

BCR-ABL point mutants isolated from patients with imatinib mesylate-resistant chronic myeloid leukemia remain sensitive to inhibitors of the BCR-ABL chaperone heat shock protein 90.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

Induction of Apoptosis in BCR/ABL+ Cells By Histone Deacetylase Inhibitors Involves Reciprocal Effects on the RAF/MEK/ERK and JNK Pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

Histone deacetylase inhibitors trigger a G2 checkpoint in normal cells that is defective in tumor cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

The histone deacetylase inhibitor MS-275 interacts synergistically with fludarabine to induce apoptosis in human leukemia cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

Cotreatment with the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) enhances imatinib-induced apoptosis of Bcr-Abl-positive human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

Cotreatment with histone deacetylase inhibitor LAQ824 enhances Apo-2L/tumor necrosis factor-related apoptosis inducing ligand-induced death inducing signaling complex activity and apoptosis of human acute leukemia cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

Synergistic induction of mitochondrial damage and apoptosis in human leukemia cells by flavopiridol and the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2403522

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/SJ.LEU.2403522

1 reference

7 December 2017

1 reference

PubMed ID

15496978